期刊文献+

拉米夫定和补肾方联合应用治疗慢性乙型肝炎的疗效及对YMDD区域的影响 被引量:22

Therapeutic Efficacy of Combined Application of Lamivudine and Bushen Recipe in Treating Chronic Hepatitis B and Its Influence on YMDD Motif
暂未订购
导出
摘要 目的:观察拉米夫定和补肾方联合应用治疗慢性乙型肝炎的疗效及对慢性乙型肝炎病毒P基因酪氨酸-蛋氨酸-天冬氨酸-天冬氨酸(YMDD)区域的影响。方法:收集乙型肝炎病毒(HBV)DNA阳性的慢性乙型肝炎患者88例,分为拉米夫定组、拉米夫定加补肾方1组和拉米夫定加补肾方2组共3组,分别检测血清HBV DNA、肝脏生化指标和P基因YMDD区域变异。结果:在治疗52周时,拉米夫定加补肾方2组无论是HBV DNA阳性率(6.45%),还是YMDD变异率(3.23%)都比拉米夫定组低。结论:初步表明,拉米夫定与补肾方联合用药能在一定程度上提高治疗慢性乙型肝炎的疗效,并可能减少YMDD的变异。 Objective: To observe the effect of combined application of Lamivudine and Bushen recipe (BSR) in treating patients with chronic hepatitis B(CHB) and its influence on tyrosine-methionine-aspartate-aspartate (YMDD) motif. Methods: Eighty-eight patients of CHB with positive HBV-DNA were divided into 3 groups, Group A treated with Lamivudine, Group B treated with Lamivudine plus BSR1 and Group C treated with Lamivudine plus BSR2, the serum HBV-DNA, hepatic biological parameters and YMDD motif mutation were observed. Results: The positive rate of HBV-DNA (6.45 % ) and YMDD motif mutation (3.23 % ) in Group C were lower than those in Group A respectively, after 52 weeks treatment. Conclusion: Combined application of Lamivudine and BSR could enhance the therapeutic effect in treating CHB to certain extent, and could reduce the mutation of YMDD motif.
出处 《中国中西医结合杂志》 CAS CSCD 北大核心 2003年第6期417-420,共4页 Chinese Journal of Integrated Traditional and Western Medicine
关键词 慢性乙型肝炎 中西医结合治疗 拉米夫定 补肾方 基因变异 hepatitis B virus, gene mutation, Lamivudine, Bushen recipe
  • 相关文献

参考文献10

  • 1孙剑.慢性乙型肝炎核苷类似物治疗过程中耐药性的产生及防治[J].国外医学(内科学分册),1998,25(10):422-425. 被引量:11
  • 2中华医学会传染病与,寄生虫病学分会,肝病学分会.病毒性肝炎防治方案[J].中华肝脏病杂志,2000,8(6):324-329. 被引量:14016
  • 3高月求,王灵台,陈建杰.补肾冲剂治疗慢性乙型肝炎的临床研究[J].上海中医药大学学报,2001,15(1):34-36. 被引量:45
  • 4王虹,万成松,王省良,彭华国.采用PCR微板核酸杂交-ELISA技术进行HBV DNA基因分型的研究[J].中华微生物学和免疫学杂志,2001,21(2):234-236. 被引量:65
  • 5Ono-Nita SK, Kato N, Shiratori Y, et al. YMDD motif in hepatitis B virus DNA polymerase influences on replication and lamivudine resistance: A study by in vitro full-length viral DNA transfection. Hepatology 1999;29:939--945.
  • 6Locarnini SA. Hepatitis B virus surface antigen and polymerase gene variants: potential virological and clinical significance. Hepatology 1998;27:294--297.
  • 7Dusheiko-G. Lamivudine therapy for hepatitis B infection.Stand J Gastroenterol 1999 ;230(Suppl) : 76--81.
  • 8Kobayashi S, Ide T, Sata M. Detection of YMDD motif mutations in some lamivudine-untreated asymptomatic hepatitis B virus carriers. J Hepatol 2001;34(4) :584--586.
  • 9Atkins M, Hunt CM, Brown N, et al. Clinical significance of YMDD mutant hepatitis B virus (HBV) in a large cohort of lamivudine-treated hepatitis B patients. Hepatology 1998;28:319A.
  • 10Chayama K, Suzuki Y, Kobayashi M, et al. Emergence and take over of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy. Hepatology 1998;27:1711--1716.

二级参考文献10

共引文献14105

同被引文献234

引证文献22

二级引证文献128

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部